NKG2D CAR-NK cells / Chongqing Sidemu Biotechnology Technology - LARVOL DELTA

piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. (PubMed, Mol Ther Methods Clin Dev) - "Collectively, our findings demonstrate the ectopic expression of IL-15 as an important means to improve the antileukemic activity of NKG2D CAR-NK cells. Our study further illustrates the feasibility of using the piggyBac non-viral platform as an efficient and cost-effective way for CAR-NK cell manufacturing."

Journal • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IL15 • NKG2D

NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. (PubMed, Blood Cancer J) - "Overall, these results demonstrate that it is feasible to modify autologous NKAE cells from MM patients to safely express a NKG2D-CAR. Additionally, autologous CAR-NKAE cells display enhanced antimyeloma activity demonstrating that they could be an effective strategy against MM supporting the development of NKG2D-CAR-NK-cell therapy for MM."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • NKG2D

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19 (clinicaltrials.gov) - P1/2; N=90; Recruiting; Sponsor: Chongqing Public Health Medical Center; Trial completion date: Sep 2020 ➔ Aug 2022; Trial primary completion date: May 2020 ➔ Feb 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • NKG2D